Karimzadeh Afshin, Bagheri Shahriar, Raeissadat Seyed Ahmad, Bagheri Shahab, Rayegani Seyed Mansoor, Rahimi-Dehgolan Shahram, Safdari Farshad, Abrishamkarzadeh Hashem, Shirzad Hadi
Department of Physical Medicine and Rehabilitation, Clinical Research Development Center of Imam-Hossein Educational Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Orthopedic Surgery, Bone, Joint and Related Tissue Research Center, Akhtar Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Pain Res. 2019 Feb 5;12:579-584. doi: 10.2147/JPR.S190652. eCollection 2019.
Local corticosteroid injection is one of the most prevalent methods in treating carpal tunnel syndrome (CTS). However, the most efficient substance and its appropriate dosage remain controversial. In the present double-blind randomized controlled trial, the efficacy and safety of local injection of two corticosteroids (triamcinolone and methylprednisolone) were compared at two different dosages, 20 and 40 mg.
We consecutively included 80 patients with mild or moderate CTS and randomly assigned them to four groups: 20 or 40 mg triamcinolone (T20 or T40) and 20 or 40 mg methylprednisolone (M20 or M40) groups; each patient received a single injection of steroid using conventional approach. The four groups were relatively comparable and did not show any significant difference initially in their baseline measurements including pain intensity measured using VAS, pain-free grip strength (PFGS), nerve conduction study (NCS), and two parts of Boston Carpal Tunnel Syndrome Questionnaire: symptom severity scale (SSS) and functional status scale (FSS); the latter was our primary outcome measure. Three months after injection, they were reassessed to evaluate the clinical and electrodiagnostic changes.
Almost all NCS parameters, VAS, and PFGS significantly improved after treatment in all the groups (<0.05). Compound motor action potential amplitude significantly improved only in T40 group (=0.032), while there was no significant improvement in other groups. Furthermore, SSS remarkably decreased in all the four groups, without any significant difference between the groups (=0.87). A similar significant decrease was found in FSS, with a higher improvement in T40 group (=0.009). There was no significant difference between the four groups in other variables after treatment.
Based on the current data, the efficacy and safety of local injection of triamcinolone and methylprednisolone at doses of 20 and 40 mg were associated with a significant improvement in pain, functional status, and strength. Although, there was no remarkable superiority, 40 mg injection, especially for triamcinolone, yielded better NCS results and functional status.
局部注射皮质类固醇是治疗腕管综合征(CTS)最常用的方法之一。然而,最有效的药物及其合适剂量仍存在争议。在本双盲随机对照试验中,比较了两种皮质类固醇(曲安奈德和甲泼尼龙)在20毫克和40毫克两种不同剂量下局部注射的疗效和安全性。
我们连续纳入80例轻度或中度CTS患者,并将他们随机分为四组:20毫克或40毫克曲安奈德组(T20或T40)以及20毫克或40毫克甲泼尼龙组(M20或M40);每位患者采用传统方法接受单次类固醇注射。四组在初始基线测量方面相对可比,包括使用视觉模拟评分法(VAS)测量的疼痛强度、无痛握力(PFGS)、神经传导研究(NCS)以及波士顿腕管综合征问卷的两个部分:症状严重程度量表(SSS)和功能状态量表(FSS);后者是我们的主要结局指标。注射后三个月,对他们进行重新评估以评估临床和电诊断变化。
治疗后,所有组的几乎所有NCS参数、VAS和PFGS均有显著改善(<0.05)。复合运动动作电位幅度仅在T40组有显著改善(=0.032),而其他组无显著改善。此外,所有四组的SSS均显著降低,组间无显著差异(=0.87)。FSS也有类似的显著降低,T40组改善程度更高(=0.009)。治疗后四组在其他变量方面无显著差异。
基于目前的数据,20毫克和40毫克剂量的曲安奈德和甲泼尼龙局部注射的疗效和安全性与疼痛、功能状态和力量的显著改善相关。虽然没有显著优势,但40毫克注射,尤其是曲安奈德,产生了更好的NCS结果和功能状态。